- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 181690, 9 pages
BALB/c Mice Vaccinated with Leishmania major Ribosomal Proteins Extracts Combined with CpG Oligodeoxynucleotides Become Resistant to Disease Caused by a Secondary Parasite Challenge
1Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, (CSIC-UAM), Nicolás Cabrera 1, Universidad Autónoma de Madrid, 28049 Madrid, Spain
2Unidad de Inmunología Viral, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Crta. Pozuelo Km 2, Majadahonda, 28220 Madrid, Spain
3Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Rua Waldemar Falcao, 121, Candeal, 40.296-710 Salvador-Bahia, Brazil
Received 22 July 2009; Revised 11 September 2009; Accepted 29 October 2009
Academic Editor: Jorge Morales-Montor
Copyright © 2010 Laura Ramírez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. L. Herwaldt, “Leishmaniasis,” Lancet, vol. 354, no. 9185, pp. 1191–1199, 1999.
- E. Handman, “Leishmaniasis: current status of vaccine development,” Clinical Microbiology Reviews, vol. 14, no. 2, pp. 229–243, 2001.
- S. L. Reiner and R. M. Locksley, “The regulation of immunity to Leishmania major,” Annual Review of Immunology, vol. 13, pp. 151–177, 1995.
- D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to Leishmania major in mice,” Nature Reviews Immunology, vol. 2, no. 11, pp. 845–858, 2002.
- K. A. Rogers, G. K. DeKrey, M. L. Mbow, R. D. Gillespie, C. I. Brodskyn, and R. G. Titus, “Type 1 and type 2 responses to Leishmania major,” FEMS Microbiology Letters, vol. 209, no. 1, pp. 1–7, 2002.
- R. N. Coler and S. G. Reed, “Second-generation vaccines against leishmaniasis,” Trends in Parasitology, vol. 21, no. 5, pp. 244–249, 2005.
- C. B. Palatnik-de-Sousa, “Vaccines for leishmaniasis in the fore coming 25 years,” Vaccine, vol. 26, no. 14, pp. 1709–1724, 2008.
- J. Kubar and K. Fragaki, “Recombinant DNA-derived Leishmania proteins: from the laboratory to the field,” Lancet Infectious Diseases, vol. 5, no. 2, pp. 107–114, 2005.
- M. Soto, L. Ramírez, M. A. Pineda, et al., “Searching genes encoding Leishmania antigens for diagnosis and protection,” Scholarly Research Exchange, vol. 2009, Article ID 173039, 2009.
- J. M. Requena, S. Iborra, J. Carrión, C. Alonso, and M. Soto, “Recent advances in vaccines for leishmaniasis,” Expert Opinion on Biological Therapy, vol. 4, no. 9, pp. 1505–1517, 2004.
- P. A. Bretscher, G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann, “Establishment of stable, cell-mediated immunity that makes “susceptible” mice resistant to Leishmania major,” Science, vol. 257, no. 5069, pp. 539–542, 1992.
- J. N. Menon and P. A. Bretscher, “Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge,” European Journal of Immunology, vol. 26, no. 1, pp. 243–249, 1996.
- T. M. Doherty and R. L. Coffman, “Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice,” Experimental Parasitology, vol. 84, no. 2, pp. 124–135, 1996.
- J. E. Uzonna, G. Wei, D. Yurkowski, and P. Bretscher, “Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease,” Journal of Immunology, vol. 167, no. 12, pp. 6967–6974, 2001.
- S. Iborra, N. Parody, D. R. Abánades, et al., “Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice,” Microbes and Infection, vol. 10, no. 10-11, pp. 1133–1141, 2008.
- D. L. Sacks, S. Hieny, and A. Sher, “Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes,” Journal of Immunology, vol. 135, no. 1, pp. 564–569, 1985.
- S. Iborra, J. Carrión, C. Anderson, C. Alonso, D. Sacks, and M. Soto, “Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice,” Infection and Immunity, vol. 73, no. 9, pp. 5842–5852, 2005.
- P. A. Buffet, A. Sulahian, Y. J. F. Garin, N. Nassar, and F. Derouin, “Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 9, pp. 2167–2168, 1995.
- E. G. Rhee, S. Mendez, J. A. Shah, et al., “Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory and T cell responses and protection against Leishmania major infection,” Journal of Experimental Medicine, vol. 195, no. 12, pp. 1565–1573, 2002.
- K. J. Stacey and J. M. Blackwell, “Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major,” Infection and Immunity, vol. 67, no. 8, pp. 3719–3726, 1999.
- P. S. Walker, T. Scharton-Kersten, A. M. Krieg, et al., “Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN--dependent mechanisms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 12, pp. 6970–6975, 1999.
- D. Sacks and S. Kamhawi, “Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis,” Annual Review of Microbiology, vol. 55, pp. 453–483, 2001.
- S. B. H. Ahmed, L. Touihri, Y. Chtourou, K. Dellagi, and C. Bahloul, “DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice,” Vaccine, vol. 27, no. 1, pp. 99–106, 2009.
- Y. Belkaid, S. Kamhawi, G. Modi, et al., “Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis,” Journal of Experimental Medicine, vol. 188, no. 10, pp. 1941–1953, 1998.
- J. Carrión, A. Nieto, M. Soto, and C. Alonso, “Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice,” Microbes and Infection, vol. 9, no. 6, pp. 735–743, 2007.
- N. Courret, T. Lang, G. Milon, and J.-C. Antoine, “Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice,” International Journal for Parasitology, vol. 33, no. 12, pp. 1373–1383, 2003.
- S. Mendez, S. K. Reckling, C. A. Piccirillo, D. Sacks, and Y. Belkaid, “Role for regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity,” Journal of Experimental Medicine, vol. 200, no. 2, pp. 201–210, 2004.
- I. Muller, “Role of T cell subsets during the recall of immunologic memory to Leishmania major,” European Journal of Immunology, vol. 22, no. 12, pp. 3063–3069, 1992.
- M. M. Kane and D. M. Mosser, “The role of IL-10 in promoting disease progression in leishmaniasis,” Journal of Immunology, vol. 166, no. 2, pp. 1141–1147, 2001.
- K. W. Moore, R. de Waal Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001.
- N. Noben-Trauth, “Susceptibility to Leishmania major infection in the absence of IL-4,” Immunology Letters, vol. 75, no. 1, pp. 41–44, 2000.
- N. Noben-Trauth, R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks, “The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major,” Journal of Immunology, vol. 170, no. 10, pp. 5152–5158, 2003.
- J. Carrión, C. Folgueira, and C. Alonso, “Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines,” Vaccine, vol. 26, no. 9, pp. 1155–1165, 2008.
- R. L. Coffman, “Mechanisms of helper T cell regulation of B-cell activity,” Annals of the New York Academy of Sciences, vol. 681, pp. 25–28, 1993.
- T. M. Doherty and R. L. Coffman, “Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major,” Journal of Immunology, vol. 150, no. 12, pp. 5476–5483, 1993.
- Y. Belkaid, C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks, “ regulatory T cells control Leishmania major persistence and immunity,” Nature, vol. 420, no. 6915, pp. 502–507, 2002.
- C. L. Greenblatt, “The present and future of vaccination for cutaneous leishmaniasis,” Progress in Clinical and Biological Research, vol. 47, pp. 259–285, 1980.
- S. Méndez, S. Gurunathan, S. Kamhawi, et al., “The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge,” Journal of Immunology, vol. 166, no. 8, pp. 5122–5128, 2001.